Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Apr 09, 2020 5:34pm
64 Views
Post# 30895955

RE:RE:Missed Opportunities

RE:RE:Missed Opportunities
RPINVESTOR1 wrote: Hi Ingiboy:-

I feel your pain. I have been a shareholder for close to 5 years and this Company is really testing my patience! As my Father liked saying - "You can measure progress but you can't measure lack of progress."
What really disturbs me is the way this psychopathic CEO behaves. Knowing full well that 99.9% of the shareholders are disappointed with the progress of the Company, he compunds the pain by making reckless or even false statements:-

November 26, 2019 News Release - Announcemts anticipated before year-end include:-
- audio visual of the dermal injector demonstrating its function and utility.

Still waiting! If you can't deliver on this commitment in 5 weeks on something which can be made on GoPro there is something seriously wrong with you.

March 11, 2020 News Release - While we have been informed that the plant is expected to be operational again in early March.....

Why are you telling me about something which is suppose to happen in early March when early March (March 11) has already passed (To me early March is March 1 - 10). Very misleading at best.

Also, talk of possible partnerships is a lot of b.s. (One partnership in the past 5 years). This from a man who would be late to his own funeral!

I think that it would be ironic if our CEO with 3,404 shares in the Company had to buy some shares from the Treasury in order to save his $20,000 / month Accounts Payable Clerk job!
At least there are a few adults associated with the Company who have a financial and/or emotional stake (ie. the founders) in Replicel. I am still optimistic!   
                         


Nicely said
Bullboard Posts